SKY-0515
Asset
Modulates RNA splicing to reduce huntingtin and PMS1 expression.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Not known
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Huntington's disease
Phase 2, Recruiting, NCT07378644, clinicaltrials.gov, Oct 17, 2026
In the full profile
- Owner and partners1
- Trials1
- Competitors8
- Aging relevance2
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.